Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← Analysis & Perspectives
MillimanNovember 10, 2026

Medicare Drug Price Negotiations Reshape PACE Pharmacy Economics

The analysis explains how Medicare's maximum fair price (MFP) negotiations, now expanding to Part B drugs in 2028, are altering pharmacy cost and revenue dynamics for PACE organizations, which serve frail dual-eligible seniors often overlapping with Medicaid managed care populations. It cautions that lower negotiated drug prices do not automatically improve margins because of complex interactions with rebates, 340B pricing, and CMS's Part D reconciliation process, urging PACE organizations to closely monitor utilization and net costs as more drugs become subject to MFP.

Pharmacy · Managed Care · Finance

Read the full analysis at Milliman →

This is outside commentary from Milliman, not part of Medicaid Monitor's independently scored news coverage.

Share this

More from Milliman

← Analysis & Perspectives

Get the daily briefing.